Resumen

This is a Phase 1b/2 study. In Phase 1b portion, subjects will know the treatment they are receiving . Subjects will receive U3-1287 with trastuzumab plus paclitaxel . The phase 1b portion will determine if adding U3-1287 to trastuzumab plus paclitaxel will be safe in subjects with metastatic breast cancer. In phase 2 portion, subjects will be blinded to the treatments they are receiving . Subjects will receive either trastuzumab plus paclitaxel with U3-1287 or trastuzumab plus paclitaxel and placebo.The phase 2 portion will determine if adding U3-1287 to trastuzumab plus paclitaxel will be safe and improve survival in subjects with metastatic breast cancer.

Elegibilidad

Edad mínima: 18 YearsSexo: FEMALE

Criterios de inclusión

Hematological function, as follows:
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
Subjects must satisfy all of the following criteria to be included in the study:
Women ≥ 18 years old.
Histologically or cytologically confirmed adenocarcinoma of the breast with metastatic disease and at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) guidelines Version 1.1.
Documented HER2+ disease as measured by FISH or IHC (3+). See Appendix 17.8 for documentation criteria.
Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
Platelet count \>100 x 109/L
Hemoglobin ≥9 g/dL.
Renal function, as follows:
\- Calculated creatinine clearance ≥60 mL/min using the modified Cockcroft Gault equation.
Hepatic function, as follows:
AST ≤2.5 x ULN (if liver metastases are present, \< 5 x ULN)
ALT ≤2.5 x ULN (if liver metastases are present, \< 5 x ULN)
Alkaline phosphatase ≤ 2.0 x ULN (if bone or liver metastases are present, \< 5 x ULN)
Bilirubin ≤1.5 x ULN.
Prothrombin time (PT) and partial thromboplastin time (PTT) ≤1.5 x ULN.
Availability of archived tumor sample or fresh tumor specimen (does not have to be provided by treatment start) to confirm HER2 status and for tumor biomarkers/mutation analysis.
Subjects must be postmenopausal (no menstrual period for a minimum of 12 months) or surgically sterile, or must use maximally effective birth control during the period of therapy, and be willing to use contraception for 6 months following the last investigational drug dose and have a negative urine or serum pregnancy test upon entry into this study if subject is of childbearing potential. Partners of subjects must be surgically sterile or willing to use a double barrier contraception method upon enrollment, during the course of the study, and for 6 months after last investigational drug dose received.
Subjects must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
Subjects must be competent and able to comprehend, sign, and date an IEC- or IRB-approved ICF before performance of any study specific procedures or tests.

Criterios de exclusión

Subjects who meet any of the following criteria will be disqualified from entering the study:
Prior treatment for metastatic disease other than radiation therapy. Neoadjuvant/adjuvant therapy with paclitaxel, and/or docetaxel, and/or trastuzumab is allowed if completed more than 12 months prior to relapse/progression.
Clinically active brain metastases, defined as untreated symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms. Subjects with treated brain metastases that are no longer symptomatic and require no treatment with steroids or anticonvulsants may be included in the study if they have recovered from the acute toxic effect of radiotherapy.
LVEF \< 50%. History of LVEF decline to \< 50% on prior trastuzumab therapy.
Therapeutic or palliative radiation therapy or major surgery within 4 weeks before study drug treatment.
History of other malignancies, except adequately treated nonmelanoma skin cancer, curatively treated in situ cancer, or other solid tumors curatively treated with no evidence of disease for ≥ 5 years.
Uncontrolled hypertension (diastolic blood pressure \> 100 mmHg or systolic blood pressure \> 140 mmHg). Use of antihypertensive medications is permissible to maintain blood pressure within the required parameters.
Clinically significant electrocardiogram (ECG) changes that obscure the ability to assess the RR, PR, QT, QTc and QRS intervals.
Subjects with left bundle branch block, atrial fibrillation and use of a cardiac pacemaker specifically will be excluded.
Ascites or pleural effusion requiring chronic medical intervention.
Pre-existing peripheral neuropathy \> grade 1.
Myocardial infarction, symptomatic CHF (New York Heart Association \> Class II), unstable angina, or unstable cardiac arrhythmia requiring medication within 1 year before enrollment.
Use of cytochrome P450 (CYP) 3A4 (CYP3A4) or CYP2C8 inducers within 28 days prior to Day 1, use of CYP3A4 or CYP2C8 inhibitors within 14 days prior to Day 1, or concurrent use of CYP3A4 or CYP2C8 inducers or inhibitors (see Appendix 17.6 for list of CYP34A and CYP2C8 inhibitors and inducers).
Use of amiodarone within 6 months prior to enrollment.
Concurrent use of antiarrhythmic medications.
Participated in clinical drug studies within 4 weeks (2 weeks for small molecule tyrosine kinase inhibitors; 6 weeks for mitomycin C and nitrosoureas) before study drug treatment. Current participation in other investigational protocols or procedures.
Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals.
Known human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection.
History of hypersensitivity to any of the study drugs or to any excipients.
Serious intercurrent medical or psychiatric illnesses or any other conditions that in the opinion of the Investigator would impair the ability to give informed consent or unacceptably reduce protocol compliance or safety of the study treatment.
Pregnant, breastfeeding, or unwilling/unable to use acceptable contraception.
QTc interval \> 450 msec by Friderica's formula on two successive screening measurements (second measurement is required if first measurement is \> 450 msec.
Personal or family history of long-QT syndrome.
Subjects who are receiving drugs that may affect QTc (eg, quinidine or moxifloxacin).

Intervenciones

drug

U3-1287

U3-1287: 18 mg/kg administered intravenously once every three weeks

drug

Trastuzumab

Trastuzumab: 6 mg/kg up to 8 mg/kg administered intravenously once every three weeks

drug

Paclitaxel

Paclitaxel: 175 mg/m\^2 administered intravenously once every three weeks

drug

U3-1287

The maximum tolerated dose as determined in Phase 1b portion (between 9 mg/kg and 18 mg/kg) administered intravenously once every three weeks

drug

Trastuzumab

Trastuzumab: 6 mg/kg up to 8 mg/kg administered intravenously once every three weeks

drug

Paclitaxel

Paclitaxel: 175 mg/m\^2 administered intravenously once every three weeks

drug

Placebo

Placebo: Dose corresponding to U3-1287 administered intravenously once every three weeks

Ubicaciones

Unidad de Investigación FP Clinical Pharma en Centro Medico Integral Fitz Roy

Acevedo, Buenos Aires F.D., Argentina

Centro Medico San Roque

San Miguel, Tucumán Province, Argentina

Hospital Britanico

Buenos Aires, Argentina

Sanatorio de la Providencia

Buenos Aires, Argentina

Instituto Damic - Fundacion Rusculleda

Córdoba, Argentina

ISIS Centro Especializado

Santa Fe, Argentina

Randomized, Placebo Controlled, Double Blind Phase 1b/2 Study of U3-1287 (AMG 888) in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed HER2 Positive Metastatic Breast Cancer (MBC)

Resumen

Elegibilidad

Criterios de inclusión

Criterios de exclusión

Intervenciones

U3-1287

Trastuzumab

Paclitaxel

U3-1287

Trastuzumab

Paclitaxel

Placebo

Ubicaciones

Unidad de Investigación FP Clinical Pharma en Centro Medico Integral Fitz Roy

Centro Medico San Roque

Hospital Britanico

Sanatorio de la Providencia

Instituto Damic - Fundacion Rusculleda

ISIS Centro Especializado

Patrocinadores